Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination between Petra Acquisition, Inc. (a special purpose acquisition company) and Revelation Biosciences, Inc. ("Old Revelation") on January 10, 2022. Following the merger, Petra changed its name to "Revelation Biosciences, Inc." ("New Revelation") and ceased to be a shell company. The combined entity is now a public operating company with its principal executive offices in San Diego, California.
Key Financial Metrics and Capital Structure
The filing details the capital structure immediately following the closing of the transaction rather than providing standard operating financial metrics like revenue or profit for the combined entity.
- Shares Outstanding: 12,944,213 shares of Common Stock were outstanding immediately after the closing.
- Merger Consideration: 10,500,000 shares of Common Stock were issued as consideration, comprising 9,871,343 shares for Old Revelation stock, 167,867 shares reserved for Rollover Warrants, and 460,706 shares reserved for Rollover RSUs.
- Redemptions: Holders of 3,480,362 shares of Petra common stock exercised their right to redeem shares for approximately $10.20 per share, totaling approximately $35.5 million in cash payments.
- Forward Purchase Agreement: Approximately $7.6 million was escrowed pursuant to a Forward Share Purchase Agreement with Meteora Special Opportunity Fund I, LP and Meteora Capital Partners, LP, with approximately $4.2 million released to the Company on the closing date.
- Warrants: 10,490,461 warrants were outstanding as of the closing date.
- Operating Metrics: The filing does not provide specific revenue, profit, or cash flow figures for the combined entity in this report; it references the Proxy Statement/Prospectus for historical and pro forma financial data.
Material Changes Versus Prior Period
The primary material change is the transition from a shell company (Petra) to an operating biopharmaceutical company (Revelation Biosciences). Key changes include:
- Corporate Identity: The registrant changed its name from Petra Acquisition, Inc. to Revelation Biosciences, Inc.
- Trading Symbols: Securities began trading on the Nasdaq Capital Market under new symbols: REVBU (Units), REVB (Common Stock), and REVBW (Warrants), replacing the previous PAICU, PAIC, and PAICW symbols.
- Ownership Structure: Pre-closing Petra stockholders hold approximately 23.7% of the post-closing Common Stock. Old Revelation stockholders received shares based on a conversion rate of 2.725.
- Board Composition: The board was reconstituted with five members, including George F. Tidmarsh, James Rolke, Jennifer Carver, Jess Roper, and Curt LaBelle. Previous Petra directors and officers ceased their roles.
Guidance, Outlook, and Risks
The filing contains a cautionary note regarding forward-looking statements, indicating that actual results may differ materially from projections due to various risks. Specific guidance on future financial performance is not included in this text; investors are directed to the Proxy Statement/Prospectus for risk factors and management discussion.
- Dividends: The Company does not anticipate paying any cash dividends in the foreseeable future.
- Risks: Risks associated with the business are incorporated by reference from the Proxy Statement/Prospectus, including risks related to the business combination and ownership of the new entity.
- Legal Proceedings: The filing states there are no legal proceedings.
Important Facts for Investor Verification
- Verify the pro forma financial information and historical financial statements of Old Revelation and Petra in the referenced Proxy Statement/Prospectus (File No. 333-259638) to assess the combined entity's financial health.
- Confirm the impact of the $35.5 million in redemptions on the Company's available cash and liquidity for operations.
- Review the terms of the Forward Share Purchase Agreement with Meteora to understand the timing and conditions of the remaining escrowed funds.
- Examine the "Risk Factors" section of the Proxy Statement/Prospectus for specific risks related to the biopharmaceutical industry and the recent merger.
- Check the vesting schedules and terms of the 1,294,421 shares reserved for future issuance under the Equity Incentive Plan.